- Ongoing progress across ongoing clinical development programs with growing body of positive preclinical and clinical data - Released Clinical Trial Update press release yesterday providing the quarter's update on its clinical activities - Company to host conference...

- Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML (MB-106) and opens the Phase 2 portion for recruitment - Announces a preliminary CR/CRi rate of 33% (n=6) in...

HOUSTON, Aug. 7, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it is investigating...

HOUSTON, Aug. 3, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its...

Data published in peer-reviewed British Journal of Cancer Research No evidence of cardiotoxicity in any subject treated in this study, including up to 16 subjects whose cumulative anthracycline dose (Annamycin included) exceeded the lifetime cumulative doxorubicin (or...

Live moderated video webcast on Wednesday, July 12th at 3:00 PM ET HOUSTON, July 6, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...

Live webcast fireside chat on Wednesday, June 21st at 1:30 PM ET HOUSTON, June 13, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for...

- Company urges shareholders of record date, March 27, 2023, to vote your shares immediately if you have not already done so HOUSTON, May 30, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a...

- Continued clinical and operational execution across ongoing development programs with growing body of positive preclinical and clinical data - Sufficient capital to fund operations into the third quarter of 2024 - Company to host conference call and webcast today at...

- Actively recruiting in three Phase 1b/2 clinical trials (one of which is in Phase 2) - Recently completed first cohort in Phase 1b/2 trial evaluating Annamycin in combination with cytarabine (Ara-C) for the treatment of acute myeloid leukemia (AML); Preliminary...